今年ASCO大会上将公布5889份摘要信息,其中5篇全体大会(Plenary Session)、213篇口头报告 (Oral Abstract Session)、 215篇快速口头报告(Rapid Oral Abstract Session)、53篇临床科学研讨会(Clinical Science Symposium) 、2668篇壁报(Poster Session )以及其他。 妇科肿瘤领...
MID-MAY 2024: Oral Abstract and Poster Presenters' deadline to submit their presentation materials (slides, posters) on ASCO'sSpeaker Center Website 口头摘要和海报演讲者在ASCO演讲者中心网站上提交演讲材料(幻灯片,海报)截止日期 MAY 23, 2024, AT 5:00 PM (ET) Regular Abstracts Released on asco....
[10] 2024 ASCO,Poster e23265 [11] Cocco E, et al. Nat Rev Clin Oncol. 2018;15:731-747. [12] Do K, et al.Chin Clin Oncol. 2015 Sep;4(3):31. Murciano-Goroff YR, et al.Cancer Cell. 2021 Jan 11;39(1...
摘要发布的专场及重磅程度:Plenary Session>Oral Abstract Session>Rapid Oral Abstract Session≈Clinical Science Symposium(CSS;少量)>Education Session (ED;少量)>Poster Session(注:仅 Poster Session 以壁报海报张贴形式公布摘要,其余均为口头汇报形式公布;CSS 与 Rapid Oral Abstract Session 的重磅程度比较暂无法...
for extensive-stage small cell lung cancer.ASCO 2024:Rapid Oral abstract 8014 6. Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. ASCO 2024:Poster abstract ...
康方生物宣布了依沃西单抗（PD-1/VEGF双抗）在PD-L1阳性NSCLC治疗中的III期研究结果，对比帕博利珠单抗（K药），PFS显著获益，若预期目标达成，有望大幅抢占K药在该适应症市场的份额。在2024 ASCO大会上，康方生物还发布了一项poster，该研究聚焦依沃西单抗联合标准化疗一线治疗胆道恶性肿瘤（BTC），疗效...
壁报(Poster Session) 摘要号:5524 英文标题:Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. 中文标题:PM8002(一种靶向...
壁报(Poster Session) 摘要号:2646 英文标题:Fecal microbiota transplantation combined with anti-PD-(L)1 inhibitors as first-line maintenance therapy for advanced gastric and non small cell lung cancer. 中文标题:粪菌移植联合抗PD-(L)1抑制剂作为晚期胃癌和NSCLC的一线维持治疗 ...
1.Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. ASCO 2024:Poster abstract 4110. 2.Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hep...
2024年5月31日,康方生物发布重磅消息,依沃西单抗(PD-1/VEGF双抗)对比帕博利珠单抗(PD-1单抗,K药)1L治疗PD-L1阳性NSCLC的III期结果,PFS获益非常显著。如果该研究最终达到预期,未来将有望大幅抢占K药在该适应症市场。而本次ASCO大会中,康方还中了一项poster,主题为依沃西单抗联合标准化疗一线治疗胆道恶性肿瘤(BTC)...